Welcome to our dedicated page for Hutchmed (China) news (Ticker: HCM), a resource for investors and traders seeking the latest updates and insights on Hutchmed (China) stock.
HUTCHMED (China) Limited (HCM) news covers the company’s ongoing work as a commercial-stage biopharmaceutical developer of targeted therapies and immunotherapies for cancer and immunological diseases. Press releases frequently describe progress across its in-house pipeline, regulatory milestones in China and abroad, and updates on marketed medicines such as ELUNATE® (fruquintinib), ORPATHYS® (savolitinib) and SULANDA® (surufatinib).
Investors and healthcare professionals following HUTCHMED news can expect detailed reports on clinical trial results, including Phase II and Phase III data in solid tumors and autoimmune hematologic diseases. Recent announcements have highlighted Phase III outcomes for savolitinib plus TAGRISSO® in EGFR-mutated non-small cell lung cancer, topline Phase III results for sovleplenib in warm antibody autoimmune hemolytic anemia, and initiation or expansion of studies such as the Phase II/III trial of surufatinib and camrelizumab in metastatic pancreatic ductal adenocarcinoma.
News items also address regulatory and reimbursement developments, such as New Drug Application acceptances with priority review for savolitinib in MET-amplified gastric cancer and fanregratinib in intrahepatic cholangiocarcinoma, as well as inclusion of HUTCHMED-associated medicines on China’s National Reimbursement Drug List and the National Commercial Health Insurance Innovative Drug List. These updates provide context on how the company’s therapies may reach broader patient populations.
Another recurring theme is platform and pipeline strategy, including announcements about the ATTC (Antibody-Targeted Therapy Conjugate) platform and first-in-human trials of HMPL-A251, as well as presentations at major scientific meetings such as ESMO, ASH and AACR-NCI-EORTC. For those tracking HCM, this news feed offers a centralized view of clinical data readouts, partnership activities, regulatory interactions and broader R&D progress. Bookmarking this page allows readers to follow how HUTCHMED’s oncology and immunology programs evolve over time.
HUTCHMED (HCM) has been added to the SEC's conclusive list under the Holding Foreign Companies Accountable Act (the Act), following its annual report filing on March 3, 2022. This designation could lead to delisting from Nasdaq in early 2024 unless compliance is achieved. The Company emphasizes that this update does not affect its operations and is committed to transparency and compliance with U.S. regulations. HUTCHMED continues to explore options to maintain U.S. listings, including potentially appointing an auditor outside China.
HUTCHMED (HCM) updates on its status under the Holding Foreign Companies Accountable Act (the Act). On March 8, 2022, the SEC provisionally identified HUTCHMED as a Commission-Identified Issuer. This designation could lead to the delisting of its American depositary shares from Nasdaq by early 2024 if its auditor remains non-inspected by the PCAOB for three consecutive years. The Company continues to monitor regulatory developments and evaluate strategic options amidst ongoing pressure from U.S. regulations.
HUTCHMED, listed as HCM, announced a $15 million milestone payment from AstraZeneca, triggered by the start of the Phase III SAFFRON study for ORPATHYS® in combination with TAGRISSO® for NSCLC patients. This brings AstraZeneca's total payments to HUTCHMED to $85 million out of a potential $140 million under their collaboration agreement. SAFFRON aims to enroll patients by mid-2022, following insights from the SAVANNAH study. The upcoming trial results will be shared at a scientific conference later in 2022.
HUTCHMED announces the retirement of CEO Christian Hogg, effective March 4, 2022, after 22 years with the company. Dr. Weiguo Su, previously Chief Scientific Officer, is appointed as the new CEO, bolstering leadership continuity. Dr. Su's tenure at HUTCHMED spans 17 years, during which he contributed to the in-house discovery of 12 oncology drug candidates, with three already approved. Hogg will transition to a strategic advisory role. His departure raises questions on continuity amidst ongoing management changes.
HUTCHMED reports a remarkable year in 2021, with oncology/immunology revenues soaring 296% to $119.6 million, driven by strong sales of ELUNATE®, SULANDA®, and ORPATHYS®. The company completed enrollment for the FRESCO-2 global Phase III study of fruquintinib and initiated multiple registration studies for ORPATHYS® in various cancers. With over $1 billion in cash, HUTCHMED plans to expand globally and launch new products. Total revenues rose 56% to $356.1 million, yet net loss increased to $194.6 million. Financial guidance for 2022 suggests oncology revenues between $160-$190 million.
HUTCHMED has received approval to market fruquintinib (ELUNATE®) in Macau, marking it as the first homegrown innovative oncology drug based on clinical data from China. This approval follows updates to drug importation regulations in Macau. Originally approved for metastatic colorectal cancer in China in September 2018, fruquintinib shows potential for further clinical applications. HUTCHMED's COO expressed optimism about patient access to this drug in Macau and its promising safety profile in combination therapies.
HUTCHMED (Nasdaq/AIM: HCM; SEHK: 13) will announce its final results for the fiscal year ending December 31, 2021, on March 3, 2022, at 7:00 am EST. Following this, a conference call and audio webcast will commence at 8:00 am EST, featuring a Q&A session with management. HUTCHMED is a biopharmaceutical company dedicated to the development of targeted therapies and immunotherapies for cancer and related diseases. The company employs over 4,600 personnel, with a focus on advancing its oncology drug candidates.
HUTCHMED has initiated a Phase Ib/II study in China for HMPL-453, a selective FGFR inhibitor, in combination with chemotherapy or toripalimab.
The trial aims to evaluate the safety and initial efficacy in patients with advanced solid tumors. The first patient was dosed on January 22, 2022. This multi-center study includes a dose escalation phase followed by a dose expansion phase targeting gastric cancer and other conditions. HUTCHMED retains all global rights to HMPL-453, which addresses key tumor growth factors and is currently involved in further clinical studies, including HMPL-453 monotherapy for intrahepatic cholangiocarcinoma.
HUTCHMED has initiated a Phase I clinical trial for HMPL-653, a selective CSF-1R inhibitor, in China as of January 18, 2022. This multicenter trial aims to evaluate the safety, tolerability, and preliminary efficacy in patients with advanced solid tumors and tenosynovial giant cell tumors (TGCT). Around 110 patients will be enrolled. With no CSF-1R inhibitors currently approved in China, this trial addresses a significant unmet medical need. HUTCHMED retains all worldwide rights to HMPL-653, furthering its commitment to innovative cancer therapies.
HUTCHMED announced that updated analysis of the ongoing Phase I/Ib trial of fruquintinib will be presented at the 2022 ASCO Gastrointestinal Cancers Symposium on January 22, 2022. The study focuses on patients with advanced solid tumors, specifically looking at the preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer. Colorectal cancer is a significant health issue worldwide, with an estimated 915,000 deaths in 2020. Fruquintinib, an oral VEGFR inhibitor, is already approved in China for metastatic CRC and is being studied for various combinations with other therapies.